News

NeuroVive announces that the 600th patient has been recruited to a pivotal Phase III European, multi-center clinical trial (CIRCUS trial) assessing CicloMulsion (a special formulation of cyclosporine for acute cardiac injuries) for the treatment of heart reperfusion injury following stenting in patients with myocardial infarction.

Home March 26, 2013
Home
News

March 26, 2013 — A multicenter analysis, led by Weill Cornell Medical College and published in the Journal of Clinical Gastroenterology, shows the use of temporary "fully covered self-expanding metal stents" (FCSEMS) can effectively fix a painful and potentially life-threatening benign biliary stricture.

Home March 26, 2013
Home
Technology

TeraMedica announced a Partner Agreement with Frontier Solutions Group. FrontierSG now offers complete VNA solutions including integrated storage products from IBM and TeraMedica’s Evercore Clinical Enterprise Suite, the leading vendor neutral archive (VNA) in the industry.

Home March 26, 2013
Home
News

In addition to improving life quality and diminishing pain, total hip replacement (THR) is associated with reduced mortality, heart failure, depression and diabetes rates in Medicare patients with osteoarthritis, according to a new study presented at the 2013 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS). The procedure also is cost effective with the seven-year costs of THR only $6,366 higher than the cost of treating an osteoarthritis patient for hip pain without THR.

Home March 25, 2013
Home
News

The American Society of Echocardiography (ASE) released a list of five interventions whose appropriateness physicians and patients should discuss as part of Choosing Wisely, an initiative of the ABIM Foundation, along with Consumer Reports. Third in the list, they ask that patients and their doctors talk about the real need for an echocardiogram when preparing for a surgery.

Home March 25, 2013
Home
News

March 25, 2013 — W. L. Gore & Associates introduced its Gore DrySeal Sheath with hydrophilic coating in Europe.

Home March 25, 2013
Home
Feature

March 25, 2013 — The largest randomized study of the vitamin niacin in patients with occlusive arterial disease (narrowing of the arteries) has shown a significant increase in adverse side effects when it is combined with statin treatment. Results from the HPS2-THRIVE study, including the reasons patients stopped the study treatment, were published online.

Home March 25, 2013
Home
Videos | Cardiovascular Information Systems (CVIS)

McKesson highlighted enhancements to its cardiovascular information system (CVIS) version 13. The system offers new ...

Home March 22, 2013
Home
News

The Medical Imaging and Technology Alliance (MITA), Advanced Medical Technology Association (AdvaMed) and the Medical Device Manufacturers Association (MDMA) applauded the adoption of an amendment to the Fiscal Year 2014 Senate Budget Resolution that expresses support for repeal of the medical device tax.

Home March 22, 2013
Home
News

A new report that breast cancer patients treated with low doses of radiation therapy have a heightened risk of heart disease suggests that physicians need to work with patients before, during, and after treatment to minimize that risk, according to an accompanying editorial in the March 14 issue of the New England Journal of Medicine.

Home March 22, 2013
Home
Technology

GE Healthcare announced the U.S. Food and Drug Administration (FDA) approval of a new indication for AdreView (Iobenguane I 123 Injection), the first and only FDA approved molecular imaging agent to link nerve function in the heart to a patient’s mortality risk.[1] AdreView is approved for the scintigraphic assessment of myocardial sympathetic innervation (cardiac nerve activity) to assist in the evaluation of patients with New York Heart Association (NYHA) Class II or Class III heart failure and left ventricular ejection fraction (LVEF) ? 35 percent.[2]

Home March 22, 2013
Home
Abbot MitraClip
Feature

Abbott announced that the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee has voted by majority (Yes: 5, No: 3) that the benefits of treatment with the MitraClip device outweigh its risks in patients with significant symptomatic mitral regurgitation (MR) who have been determined by a cardiac surgeon to be too high risk for open mitral valve surgery and in whom existing co-morbidities would not preclude the expected benefit from correction of the MR.

Home March 22, 2013
Home
News

Network security issues, vital infrastructure upgrades, electronic health record (EHR) implementation and impending federal deadlines will guide priorities this year, according to an independent research study of 100 healthcare provider CIOs and senior IT executives that was commissioned by Level 3 Communications Inc.

Home March 22, 2013
Home
Technology

Guerbet announced that the U.S. Food and Drug Administration (FDA) has approved Dotarem (gadoterate meglumine), a gadolinium-based contrast agent (GBCA) indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

Home March 22, 2013
Home
ACC HRS Appropriate Use Criteria ICDs CRTs
Feature

The American College of Cardiology (ACC) and Heart Rhythm Society (HRS), along with key specialty societies, released appropriate use criteria for implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT) devices.

Home March 21, 2013
Home
Subscribe Now